RedHawk Holdings Corp. SNDD Message Board

https://www.otcmarkets.com/stock/SNDD/security


'times2'
due diligence reposting

Updates: Sales of SANDD mini™ device; Famous DR. Drew as consultant and spokesperson; Debt elimination, international subsidies with improved revenues; HAWK as new trading symbol soon; Float t.b. reduced by ~10%; Warrants (at half a cent) now held by Institutional Investor/Beechwood

OS 872M 08/22/2019; AS 2000M

SEC Reporting/Audited Financials

News Aug 22 2019 8K: Employee Benefit plan - Dr Drew Pinsky, Consultant, will own 54,960,000 of 872,009,097 shares of common stock outstanding as of August 21, 2019 (BTW no change in OS in a month/ resp. no dilution)
DR. Drew as shareholder - he will hold ~ 20% of the float, the other employees/management hold mostly restricted common shares
https://ih.advfn.com/stock-market/USOTC/indep...t-plan-s-8

News July 25 2019 8K: RedHawk Medical Products & Services LLC entered into a Consultant Agreement (“Agreement”) with Drew Pinsky, Inc. (“DPI”) f/s/o Dr. Drew Pinsky, for Consultant to be the exclusive spokesperson for the Company’s Sharps Needle and Destruction Device (“ SAN DD”) mini™, SAN DD Pro™ and any related products and/or accessories (“Products”) for an initial period of two years.
https://www.otcmarkets.com/filing/conv_pdf?id...pZDTYxu3th

News June 24 2019 8K: Debt eliminated: Holders of $574,250 aggregate principal amount of the Company’s 5% convertible promissory notes, including accrued interest, have converted their Notes into 114,849,929 shares of Common Stock
https://ih.advfn.com/stock-market/USOTC/indep...filing-8-k

News June 24 2019 8K: Warrants at half a cent - Beechwood now holds a Stock Purchase Warrant (“Warrant”) to acquire 113,508,450 shares of Common Stock at an exercise price of $0.005 per share. The Warrant expires June 20, 2029.
https://ih.advfn.com/stock-market/USOTC/indep...filing-8-k

Revenues in the pharmaceutical and medical device business unit are expected to improve as market acceptance of our products increases and we begin sales of our SANDD medical devices. Additionally, net profits are expected to improve as the Company’s pharmaceutical sales become more weighted to its branded generics which offer lower discounts than the discounts offered by the Company for its highly competitive “special” pharmaceuticals and require significantly lower operating costs. Additionally, our medical devices are being offered for sale at very attractive profit margins.
https://www.otcmarkets.com/stock/IDNG/security

News June 17, 2019 RedHawk Holdings Corp. announced today that it has engaged Black Mountain Pharma Ltd. to assist RedHawk Medical Products and Services, LLC and RedHawk Medical Products UK Ltd (collectively referred to herein as "RedHawk Medical Products" , wholly-owned subsidiaries of the Company, in the transition and ongoing maintenance of its current FDA-approved quality management system to the higher and more stringent international medical device standard, ISO 13485:2016.
Black Mountain Pharma Ltd (www.blackmountainpharma.com) was established in 2012 to provide professional Regulatory Affairs ("RA" and Quality Assurance ("QA" support for developing, implementing and sustaining quality management systems and for establishing regulatory affairs strategies for businesses associated with medical devices, pharmaceuticals, cosmetics and foods.
Led by Dr. Christopher W. Smejkal, the Black Mountain global team of professionals has a long history of developing, implementing and sustaining management systems and establishing regulatory affairs strategies for businesses associated with medical devices and pharmaceuticals. Dr. Christopher Smejkal from Black Mountain Pharma Ltd has joined RedHawk as its RA/QA consultant. He will act as the Company's Responsible Person for distribution of branded generic pharmaceuticals in the UK. Dr. Smejkal holds Bachelor of Science and Doctor of Philosophy (PhD) degrees in Biological Sciences from the University of Exeter, United Kingdom and a Master of Business Administration degree from the Open University, United Kingdom. He has extensive experience working in both the medical device and pharmaceutical industries as a senior RA/QA Professional.

As RedHawk Medical Products' business focuses on the development and sales of the Sharps and Needle Disintegration Devices (SANDD™) line of products, ISO 13485:2016 will become an integral part of RedHawk Medical Products' business culture and the way in which it operates.
ISO 13485 was specifically developed with the objective of harmonizing medical device regulatory requirements for quality management systems in major markets around the world including the United States, Europe, Canada, Japan and Australia. ISO 13485 and meets, or exceeds, all U.S. Food and Drug Administration Quality System Regulations Standard 21 CFR 820 which was established in 1978 to outline Current Good Manufacturing Practices in the United States.

News June 13, 2019: REDHAWK HOLDINGS CORP. announced today the appointment of Philip C. Spizale to its board of directors ("Board" effective July 1, 2019. Mr. Spizale has more than 25 years of sales, marketing and management experience in the healthcare industry and has served as a healthcare advisor to the Board since November 2017. Mr. Spizale will assist the Company in developing its sales and marketing strategies for its line of SANDD™ needle incineration units.
In 2016, Mr. Spizale joined REVA, Inc., the largest fixed wing air medical transport service provider in the Americas, as its Chief Sales Officer. Prior to joining REVA, Inc., Mr. Spizale held various senior sales and managerial positions with Concentra Inc. between 2003 and 2016. Concentra Inc. is a national health care provider of a wide range of medical services to employers and patients, including urgent care, occupational medicine, physical therapy, primary care, and wellness programs.

We are currently accepting orders for our SANDD mini™ and within the next thirty (30) days, we plan to commence deliveries of the SANDD mini™ into the Texas school systems."

The Company also announced today that it has completed the acquisition of the following internet domains – hawc.com, sanddmini.com, sanddpro.com and instantreassurance.com.
https://ih.advfn.com/stock-market/USOTC/indep...-redhawk-b

News May 10, 2019: RedHawk Expands Sandd Sales Infrastructure
https://www.otcmarkets.com/stock/IDNG/news/st...id=1354800
LAFAYETTE, LA / ACCESSWIRE /RedHawk Holdings Corp. (OTC PINK: IDNG) ("RedHawk" or the "Company" announced today that it has entered into a customer-specific sales representation agreement with Jeeds Health, Inc., an affiliate of Pharmaceutical Buyers, Inc. ( "PBI" - www.pharmaceuticalbuyersinc.com ), for the sale of its SANDD mini ("Sharps and Needle Destruction Device" needle destruction devices. The Company believes the agreement will eventually extend to the SANDD Pro unit when it is offered for sale later in 2019.

PBI, a New York-based company headquartered in Long Island, New York, sources and distributes clinical trial, biologic and specialty drugs to approximately 285 major pharmaceutical and biotech companies in the United States and overseas. Through an affiliate, R&H Pharmacy, PBI distributes prescription, medication, vitamins, supplements and over-the-counter items to various wholesalers in the European Union.

PBI serves an active base of about 285 major pharmaceutical related companies in the United States and in over 30 other countries in the branded, generic and biotech/pharmaceutical industry and include virtually all major generic drug manufacturers

Landmark update: Law suit, which caused the pps drop over a year, settled 3/25/2019 https://ih.advfn.com/stock-market/USOTC/indep...1541627246 - also leading to return of 52M shares to the treasury

RedHawk Holdings Corp. 5/4/19 By Stockmarkerquarter - independent profiler on emerging growth companies:
https://stockmarketquarter.com/
RedHawk Holdings Corp., formerly Independence Energy Corp., is a diversified holding company which, through its subsidiaries, is engaged in sales and distribution of medical devices, sales of branded generic pharmaceutical drugs, commercial real estate investment and leasing, sales of point of entry full-body security systems, and specialized financial services. Through its medical products business unit, the Company sells WoundClot Surgical - Advanced Bleeding Control, the SANDD Needle Destruction Unit (formerly known as the Disintegrator), the Carotid Artery Digital Non-Contact Thermometer and Zonis. Through our United Kingdom based subsidiary, we manufacture and market branded generic pharmaceuticals. Its real estate leasing revenues are generated from various commercial properties under long-term lease. Additionally, RedHawk's real estate investment unit holds limited liability company interest in various commercial restoration projects in Hawaii. The Company's financial service revenue is from brokerage services earned in connection with debt placement services. RedHawk Energy holds the exclusive U.S. manufacturing and distribution rights for the Centri Controlled Entry System, a unique, closed cabinet, nominal dose transmission full body x-ray scanner. http://www.redhawkenergycorp.com

The Company said its health care business unit will operate as a fully-owned subsidiary of RedHawk under the name Independence Health Corp., LLC. The Company is waiting for regulatory approval to begin trading under its new trading symbol (HAWC) and new CUSIP number (75746Q103).

List of IDNG/REDHAWK subsidiaries:

Medical:
RedHawk Medical Products & Service
(https://www.needledestructiondevice.com/)

RedHawk Medical Products UK
(http://redhawkmedical.co.uk)

Pharma:
RedHawk Pharma, LLC & RedHawk Pharma UK LTD (owning majority stake of ICE Pharma group/EcoGen Europe LTD; http://icepharmagroup.com/)

Other:
RedHawk Energy Corp., LLC
(http://redhawkenergycorp.com)


DR. Drew's Consultant & Spokesperson agreement:
This sets forth the agreement dated as of July 19, 2019 between RedHawk Holdings Corp., RedHawk Medical Products & Services LLC, and any related or affiliated entities (individually and collectively, “RedHawk”), on one side, and Drew Pinsky, Inc. (“DPI”) f/s/o Dr. Drew Pinsky following terms and conditions for Consultant to be the exclusive spokesperson for the SANDD mini needle incineration unit, SANDD Pro needle incineration unit and any related products and/or accessories (individually and collectively, the “Product”).
https://www.otcmarkets.com/filing/conv_pdf?id...KL-szc4E3h
https://twitter.com/drdrew
For good and valuable consideration, the parties hereby agree as follows:
1. For the Product video testimonials (one to three, 2-3 minute spots and one 30 minute infomercial) featuring Consultant (individually and collectively
“Spots” herein), The test period will be 90 days, then an additional 30 days only if any corrective action or edits on the Spots are necessary.
2. The Product Spots test period will commence no later than September 15, 2019.
3. Territory: Worldwide.
4. The initial period (“Initial Period”) shall commence as of the date hereof and shall continue for a period of two (2) years following the commencement of the “Campaign” which shall be deemed to start on any initial broadcast/distribution/airing/mailing of the Spots following the test period, publicity/promotion materials, social media or other media using Consultant’s name and/or likeness in connection with Product (“Media Materials”) following the test period. However, in all events the Campaign shall be commenced no later than 90 days after the test period ends.
There shall be an automatic, immediately consecutive two (2)-year extension period (“Extension Period”) which shall commence upon the expiration of the Initial Period unless DPI sends RedHawk written notice of DPI’s intention to not extend at least 60 days prior to the end of the Initial Period. The Initial Period and the Extension Period are sometimes individually and collectively referred to as the “Media Period” herein. The “Term” of this agreement shall commence as of the date hereof and continue for the duration of the Media Period and for one (1) year thereafter for the collection and payment of the “Royalty” (as defined below).
5. Media/Usage: Product Spots, Direct Response TV commercials, Audiovisual Digital platforms, Search Engine Marketing, Social Media, PR, email to
existing customers of RedHawk or 3 rd party agencies opt-in email lists who have opted to receive emails ( not any unsolicited or so-called spam emails or
email blasts) and Product inserts shall all solely be in connection with marketing, promotion and advertising of the Product


(a) Consultant shall provide six (6) social media posts during each year of the Media Period that will be organic and honest (RedHawk shall be responsible for FTC compliance, e.g. , #sponsored, etc.) and RedHawk acknowledges that what Consultant posts must be truthful, factual and conform with FTC or any other governmental or medical entity rules, regulations and guidelines.
(b) DPI shall additionally furnish the services of Consultant to perform the following services as brand ambassador for the Product:
(i) provide video testimonial in the Spots for the Products;
(ii) provide up to two (2) posts monthly on Twitter, Instagram, FB, etc.;
(iii) two (2) mutually approved appearances annually subject to Consultant’s reasonable availability; and
(iv) such other additional posts, services, appearances, etc., as mutually agreed to by Consultant and RedHawk